https://www.pharmaradar360.com/article/drug-label-update-evereden-kids-mineral-sunscreen-spf-30-bd2e8f7ef3f473aaPharma Surgeen2026-07-01T00:00:00.000ZDrug label update: Evereden Kids Mineral Sunscreen SPF 30https://www.pharmaradar360.com/article/drug-label-update-guna-virus-3eb3bf9cba150338Pharma Surgeen2026-07-01T00:00:00.000ZDrug label update: GUNA-VIRUShttps://www.pharmaradar360.com/article/artrosis-canina-desarrollan-un-tratamiento-a-base-de-cartilago-de-tiburon-e59f38c3f467adf5Pharma Surgeen2026-06-30T16:21:16.000ZArtrosis canina: desarrollan un tratamiento a base de cartílago de tiburónhttps://www.pharmaradar360.com/article/improving-clinical-trial-site-collaboration-with-connected-study-startup-workflo-da3f9130544e6465Pharma Surgeen2026-06-30T16:10:58.000ZImproving Clinical Trial Site Collaboration with Connected Study Startup Workflowshttps://www.pharmaradar360.com/article/fda-selects-seven-pharmaceutical-companies-for-precheck-supply-chain-pilot-progr-0a2c6d79644ccb92Pharma Surgeen2026-06-30T16:07:47.000ZFDA Selects Seven Pharmaceutical Companies for PreCheck Supply Chain Pilot Programhttps://www.pharmaradar360.com/article/ean-2026-new-fintepla-data-in-dravet-syndrome-and-lgs-2e1731dabde52e0cPharma Surgeen2026-06-30T16:04:22.000ZEAN 2026: New Fintepla data in Dravet Syndrome and LGShttps://www.pharmaradar360.com/article/intermountain-foundation-adds-five-prominent-leaders-to-board-of-trustees-signal-4a9c1c767b095410Pharma Surgeen2026-06-30T16:02:02.000ZIntermountain Foundation Adds Five Prominent Leaders to Board of Trustees, Signaling Momentum for Major Health Care Campaignshttps://www.pharmaradar360.com/article/agc-biologics-expands-to-fill-finish-in-u-s-through-strategic-partnership-with-p-0f5f29f984e37195Pharma Surgeen2026-06-30T16:00:01.000ZAGC Biologics Expands to Fill-Finish in U.S. Through Strategic Partnership with Pyramid Pharma Serviceshttps://www.pharmaradar360.com/article/is-there-a-link-between-faster-ageing-and-early-onset-cancer-risk-f54010f77b76408bPharma Surgeen2026-06-30T15:46:48.000ZIs there a link between faster ageing and early-onset cancer risk?https://www.pharmaradar360.com/article/regina-gerdes-verlasst-das-universitatsspital-zurich-cc085937987258acPharma Surgeen2026-06-30T15:29:18.000ZRegina Gerdes verlässt das Universitätsspital Zürichhttps://www.pharmaradar360.com/article/seven-companies-selected-for-fda-pilot-to-strengthen-us-drug-supply-chain-5fdad739b5437749Pharma Surgeen2026-06-30T15:24:07.000ZSeven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chainhttps://www.pharmaradar360.com/article/imviva-biotech-gains-fda-ide-authorization-for-clonoseq-assay-in-tenacity-01-cli-d9ddbf93a50d7693Pharma Surgeen2026-06-30T15:20:45.000ZImviva Biotech Gains FDA IDE Authorization for clonoSEQ Assay in TENACITY-01 Clinical Trialhttps://www.pharmaradar360.com/article/two-roads-diverged-24f43ad0aa85acddPharma Surgeen2026-06-30T15:13:39.000ZTwo Roads Divergedhttps://www.pharmaradar360.com/article/unmc-to-host-america-250-event-today-89b6e304fa954cf2Pharma Surgeen2026-06-30T15:07:14.000ZUNMC to host America 250 event todayhttps://www.pharmaradar360.com/article/why-is-unicycive-therapeutics-stock-falling-tuesday-6f7394d18cab19b9Pharma Surgeen2026-06-30T15:04:03.000ZWhy Is Unicycive Therapeutics Stock Falling Tuesday?https://www.pharmaradar360.com/article/2-pa-pharmaceutical-facilities-to-close-lay-off-173-people-f062826ca38e4ce6Pharma Surgeen2026-06-30T15:04:00.000Z2 Pa. pharmaceutical facilities to close, lay off 173 peoplehttps://www.pharmaradar360.com/article/binghamton-university-research-study-advances-treatment-for-duchenne-muscular-dy-e204fbe6b0a80ef3Pharma Surgeen2026-06-30T15:03:11.000ZBinghamton University research study advances treatment for Duchenne muscular dystrophyhttps://www.pharmaradar360.com/article/field-safety-notices-22-to-26-june-2026-d746e3fea56fb046Pharma Surgeen2026-06-30T15:02:35.000ZField Safety Notices: 22 to 26 June 2026https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-06-30T15:00:02.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/federal-drug-research-profits-taxpayers-get-little-return-559b88021d580e01Pharma Surgeen2026-06-30T14:58:23.000ZFederal Drug Research Profits: Taxpayers Get Little Returnhttps://www.pharmaradar360.com/article/medical-journal-retracts-tavneos-pivotal-study-article-complicating-amgen-s-defe-65d94e4f861428e5Pharma Surgeen2026-06-30T14:57:24.000ZMedical journal retracts Tavneos pivotal study article, complicating Amgen’s defense efforthttps://www.pharmaradar360.com/article/bio-outshines-world-cup-as-biotech-celebrates-50th-anniversary-with-a-call-to-ac-a7808e7c581acbb8Pharma Surgeen2026-06-30T14:47:41.000ZBIO outshines World Cup as biotech celebrates 50th anniversary with a ‘call to action’https://www.pharmaradar360.com/article/inside-the-lab-spotlight-on-molecular-innovation-q-a-with-el-mustapha-bahassi-ph-49027cc84d5a21e3Pharma Surgeen2026-06-30T14:30:39.000ZInside the Lab: Spotlight on Molecular Innovation – Q&A with El Mustapha Bahassi, PhDhttps://www.pharmaradar360.com/article/abivax-rebounds-from-stock-drop-with-safety-data-for-much-hyped-colitis-prospect-31054442ec497586Pharma Surgeen2026-06-30T14:27:07.000ZAbivax rebounds from stock drop with safety data for much-hyped colitis prospecthttps://www.pharmaradar360.com/article/unicycive-gets-fda-crl-for-olc-kidney-drug-application-41ff190728dcef42Pharma Surgeen2026-06-30T14:23:07.000ZUnicycive gets FDA CRL for OLC kidney drug applicationhttps://www.pharmaradar360.com/article/baltimore-ravens-te-mark-andrews-reveals-new-partnership-biotech-company-to-rais-0832947571719282Pharma Surgeen2026-06-30T14:21:12.000ZBaltimore Ravens TE Mark Andrews Reveals New Partnership Biotech Company to Raise Awarenesshttps://www.pharmaradar360.com/article/tsingke-biotech-hosts-shanghai-salon-on-oligonucleotide-drugs-spotlighting-next-12dd061d8d31f80bPharma Surgeen2026-06-30T14:17:00.000ZTsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeuticshttps://www.pharmaradar360.com/article/altasciences-supports-key-development-milestone-for-steel-therapeutics-lead-ther-ce85454673e808d6Pharma Surgeen2026-06-30T14:12:35.000ZAltasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™https://www.pharmaradar360.com/article/strong-torso-muscles-linked-to-lower-heart-attack-risk-130e40aad7331151Pharma Surgeen2026-06-30T14:10:36.000ZStrong torso muscles linked to lower heart attack riskhttps://www.pharmaradar360.com/article/fda-chooses-7-companies-for-precheck-pilot-a37c0637582369f9Pharma Surgeen2026-06-30T14:06:01.000ZFDA Chooses 7 Companies for PreCheck Pilothttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-unicycive-s-kidney-disease-drug-d8c1230b7a325b92Pharma Surgeen2026-06-30T13:59:54.000ZUS FDA declines to approve Unicycive's kidney disease drughttps://www.pharmaradar360.com/article/vistagen-fails-another-phase-3-social-anxiety-trial-but-spies-path-to-market-c34a88ae1450a753Pharma Surgeen2026-06-30T13:48:44.000ZVistagen fails another phase 3 social anxiety trial but spies path to markethttps://www.pharmaradar360.com/article/compras-y-contrataciones-0b7232beb334c89dPharma Surgeen2026-06-30T13:43:41.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/investors-double-down-on-bain-backed-startup-de328e3c1c0235b1Pharma Surgeen2026-06-30T13:41:50.000ZInvestors double down on Bain-backed startuphttps://www.pharmaradar360.com/article/documentation-reliability-across-contractors-a-quality-systems-approach-2b727f7dbaba309cPharma Surgeen2026-06-30T13:41:01.000ZDocumentation Reliability Across Contractors: A Quality Systems Approachhttps://www.pharmaradar360.com/article/4705-1184c417894643bbPharma Surgeen2026-06-30T13:40:22.000Z4705https://www.pharmaradar360.com/article/students-call-this-massey-award-winner-a-bright-light-3e0f4f2f2863a26dPharma Surgeen2026-06-30T13:38:30.000ZStudents call this Massey Award winner ‘a bright light’https://www.pharmaradar360.com/article/ai-is-transforming-drug-discovery-here-is-the-next-trillion-dollar-biotech-oppor-ff191c1b3f0d40b6Pharma Surgeen2026-06-30T13:38:29.000ZAI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunityhttps://www.pharmaradar360.com/article/medicare-obesity-drug-coverage-puts-these-3-biotech-stocks-in-focus-a56edc0fa670ed0dPharma Surgeen2026-06-30T13:29:27.000ZMedicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focushttps://www.pharmaradar360.com/article/is-maplight-therapeutics-inc-mplt-stock-a-biotech-opportunity-ahead-of-the-zephy-0e3fc5f3a1042893Pharma Surgeen2026-06-30T13:22:31.000ZIs MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?https://www.pharmaradar360.com/article/these-biotechs-just-landed-big-fundraising-hauls-here-s-what-they-pitched-to-inv-f2063428c5478c81Pharma Surgeen2026-06-30T13:21:36.000ZThese biotechs just landed big fundraising hauls. Here’s what they pitched to investors.https://www.pharmaradar360.com/article/wipo-ifpma-and-interpat-join-forces-to-support-health-innovation-through-ip-mana-8ad4d8a55fa44a81Pharma Surgeen2026-06-30T13:21:17.000ZWIPO, IFPMA and Interpat join forces to support health innovation through IP management clinicshttps://www.pharmaradar360.com/article/beca-cecilia-grierson-2027-2028-para-realizar-una-maestria-en-irlanda-f77c1c8fbecf9239Pharma Surgeen2026-06-30T13:17:48.000ZBeca Cecilia Grierson 2027-2028 para realizar una maestría en Irlandahttps://www.pharmaradar360.com/article/is-takeda-pharmaceutical-company-limited-tak-stock-positioned-for-growth-after-s-7c82962b513a2d31Pharma Surgeen2026-06-30T13:10:47.000ZIs Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?https://www.pharmaradar360.com/article/mhra-safety-roundup-june-2026-1e23d3ea58323ea4Pharma Surgeen2026-06-30T13:09:46.000ZMHRA Safety Roundup: June 2026https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-limited-teva-stock-undervalued-after-recent-pu-34cdcaaf07315259Pharma Surgeen2026-06-30T13:08:14.000ZIs Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?https://www.pharmaradar360.com/article/is-tyra-biosciences-inc-tyra-stock-a-biotech-opportunity-ahead-of-key-surf302-tr-6159cc3952a1bbe4Pharma Surgeen2026-06-30T13:07:04.000ZIs Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?https://www.pharmaradar360.com/article/nutricette-insalata-estiva-di-ceci-cetriolo-avocado-e-menta-d2388c94bd78e0f1Pharma Surgeen2026-06-30T13:07:00.000Z#NUTRICETTE. Insalata estiva di ceci, cetriolo, avocado e mentahttps://www.pharmaradar360.com/article/is-syndax-pharmaceuticals-inc-sndx-stock-still-a-biotech-opportunity-after-revis-5a0fad92d115cd55Pharma Surgeen2026-06-30T13:06:47.000ZIs Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?https://www.pharmaradar360.com/article/is-janux-therapeutics-inc-janx-stock-a-biotech-opportunity-with-next-generation-170ece70e4c7a5bePharma Surgeen2026-06-30T13:06:39.000ZIs Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?https://www.pharmaradar360.com/article/unicycive-turned-away-by-fda-again-over-manufacturer-s-plant-shortfalls-126a7f126c063722Pharma Surgeen2026-06-30T13:03:00.000ZUnicycive turned away by FDA again over manufacturer’s plant shortfallshttps://www.pharmaradar360.com/article/ufrj-lamenta-a-morte-do-professor-emerito-luiz-felipe-alvahydo-de-ulhoa-canto-bff04f628f709459Pharma Surgeen2026-06-30T13:00:39.000ZUFRJ lamenta a morte do professor emérito Luiz Felipe Alvahydo de Ulhoa Cantohttps://www.pharmaradar360.com/article/repurposed-epilepsy-drug-could-be-used-to-boost-vaccine-protection-among-elderly-029d34c81d97ef11Pharma Surgeen2026-06-30T13:00:00.000ZRepurposed epilepsy drug could be used to boost vaccine protection among elderlyhttps://www.pharmaradar360.com/article/trinity-biotech-s-ai-cooling-unit-wins-open-compute-project-backing-de8bcbae211e7db1Pharma Surgeen2026-06-30T13:00:00.000ZTrinity Biotech’s AI cooling unit wins Open Compute Project backinghttps://www.pharmaradar360.com/article/how-the-stars-aligned-for-cece-s-spinal-cord-tumor-care-a73bb4dc284cd9a8Pharma Surgeen2026-06-30T13:00:00.000ZHow the stars aligned for CeCe’s spinal cord tumor carehttps://www.pharmaradar360.com/article/alli-donde-el-bosque-se-abre-al-universo-el-planetario-cumple-13-anos-34b1d1af86689ac7Pharma Surgeen2026-06-30T12:58:11.000ZAllí donde el bosque se abre al universo. El Planetario cumple 13 añoshttps://www.pharmaradar360.com/article/la-unlp-realizara-una-jornada-de-asesoramiento-previsional-fcdcd3af8da9158fPharma Surgeen2026-06-30T12:58:01.000ZLa UNLP realizará una jornada de asesoramiento previsionalhttps://www.pharmaradar360.com/article/crews-respond-to-fire-hazmat-situation-at-cherry-hill-pharmaceutical-facility-4e4cb93e1fa61c74Pharma Surgeen2026-06-30T12:55:45.000ZCrews respond to fire, hazmat situation at Cherry Hill pharmaceutical facilityhttps://www.pharmaradar360.com/article/la-unlp-fortalece-vinculos-academicos-y-culturales-con-turquia-b00aff28b9cfee5ePharma Surgeen2026-06-30T12:53:39.000ZLa UNLP fortalece vínculos académicos y culturales con Turquíahttps://www.pharmaradar360.com/article/simplified-c-glycosides-synthesis-could-transform-diabetes-drug-manufacturing-ef2ec9c77ec484baPharma Surgeen2026-06-30T12:52:55.000ZSimplified C-glycosides synthesis could transform diabetes drug manufacturinghttps://www.pharmaradar360.com/article/unicycive-shares-plunge-after-fda-issues-complete-response-letter-for-kidney-dis-cbe50cddf717fb35Pharma Surgeen2026-06-30T12:42:46.000ZUnicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)https://www.pharmaradar360.com/article/biotech-investor-pumps-the-brakes-on-ai-drug-discovery-88d76ca530f3fd4cPharma Surgeen2026-06-30T12:32:18.000ZBiotech Investor Pumps the Brakes on AI Drug Discoveryhttps://www.pharmaradar360.com/article/moleculin-biotech-nasdaq-mbrx-raises-2-7m-as-1-36m-warrants-are-exercised-ad07102729f2d7abPharma Surgeen2026-06-30T12:30:21.000ZMoleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercisedhttps://www.pharmaradar360.com/article/lb-pharmaceuticals-names-christopher-zergebel-as-svp-by-investing-com-431857316e89cbdaPharma Surgeen2026-06-30T12:29:26.000ZLB Pharmaceuticals names Christopher Zergebel as SVP By Investing.comhttps://www.pharmaradar360.com/article/candel-therapeutics-initiates-phase-3-lung-cancer-trial-by-investing-com-ec3f29391dd3285dPharma Surgeen2026-06-30T12:29:25.000ZCandel Therapeutics initiates phase 3 lung cancer trial By Investing.comhttps://www.pharmaradar360.com/article/candel-therapeutics-announces-initiation-of-global-pivotal-phase-3-aurora-trial-19829dfd9dfcfcacPharma Surgeen2026-06-30T12:25:20.000ZCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitorshttps://www.pharmaradar360.com/article/fda-seizes-destroys-food-worth-rs-13-71-lakh-in-pune-solapur-crackdown-66f7e6084a16dcf9Pharma Surgeen2026-06-30T12:23:50.000ZFDA Seizes, Destroys Food Worth Rs 13.71 Lakh in Pune, Solapur Crackdownhttps://www.pharmaradar360.com/article/l-industrie-pharmaceutique-poursuit-son-engagement-en-faveur-de-l-insertion-et-d-bd07dadd27c37176Pharma Surgeen2026-06-30T12:21:25.000ZL’industrie pharmaceutique poursuit son engagement en faveur de l’insertion et de l’emploi des personnes en situation de handicaphttps://www.pharmaradar360.com/article/llega-experiencia-ciytt-2026-e57831a2b96e4994Pharma Surgeen2026-06-30T12:21:14.000ZLlega Experiencia CIyTT 2026https://www.pharmaradar360.com/article/an-international-consensus-article-establishes-clinical-trial-design-in-liver-ca-043e7874df5020f9Pharma Surgeen2026-06-30T12:21:00.000ZAn international consensus article establishes clinical trial design in liver cancerhttps://www.pharmaradar360.com/article/la-unlp-en-el-lanzamiento-de-un-programa-de-formacion-legislativa-5fa260ff98b4f149Pharma Surgeen2026-06-30T12:14:50.000ZLa UNLP en el lanzamiento de un programa de formación legislativahttps://www.pharmaradar360.com/article/economic-outlook-rotterdam-2026-city-faces-fundamental-choices-to-future-proof-i-c8b368e5aba6b76aPharma Surgeen2026-06-30T12:13:51.000ZEconomic Outlook Rotterdam 2026: City faces fundamental choices to future-proof its economyhttps://www.pharmaradar360.com/article/new-top-250-report-reveals-how-the-dutch-growth-landscape-has-fundamentally-chan-4bde03f2170f97b0Pharma Surgeen2026-06-30T12:10:00.000ZNew Top 250 Report Reveals how the Dutch growth landscape has fundamentally changed in 10 yearshttps://www.pharmaradar360.com/article/definium-s-phase-3-lsd-win-is-real-the-fracture-it-exposed-is-bigger-9db94cc6742c42e9Pharma Surgeen2026-06-30T12:07:11.000ZDefinium’s Phase 3 LSD Win Is Real. The Fracture It Exposed Is Bigger.https://www.pharmaradar360.com/article/candel-opens-global-phase-3-aurora-trial-in-lung-cancer-f03abb92d680583ePharma Surgeen2026-06-30T12:05:00.000ZCandel opens global phase 3 AURORA trial in lung cancerhttps://www.pharmaradar360.com/article/programa-libros-de-catedra-d21e3714da120a10Pharma Surgeen2026-06-30T12:04:47.000ZPrograma Libros de cátedrahttps://www.pharmaradar360.com/article/rare-ageing-disorder-links-biological-clock-to-disease-76e03d8d76ee96adPharma Surgeen2026-06-30T12:03:02.000ZRare ageing disorder links ‘biological clock’ to diseasehttps://www.pharmaradar360.com/article/the-little-red-galaxies-that-may-be-sending-us-neutrinos-2a07d02e963bf3e5Pharma Surgeen2026-06-30T12:00:00.000ZThe little red galaxies that may be sending us neutrinoshttps://www.pharmaradar360.com/article/kyoto-university-international-symposium-frontiers-in-biofunction-cb2c3cc71e8df55aPharma Surgeen2026-06-30T12:00:00.000ZKyoto University International Symposium: Frontiers in Biofunctionhttps://www.pharmaradar360.com/article/research-acceleration-program-kakenhi-writing-seminar-for-early-stage-researcher-b8150777da9b0dc1Pharma Surgeen2026-06-30T12:00:00.000ZResearch Acceleration Program: KAKENHI Writing Seminar for Early-stage Researchershttps://www.pharmaradar360.com/article/vistagen-announces-topline-and-post-hoc-data-from-palisade-4-phase-3-public-spea-6085f68ed0b57abbPharma Surgeen2026-06-30T12:00:00.000ZVistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorderhttps://www.pharmaradar360.com/article/class-3-medicines-recall-flamingo-pharma-uk-ltd-flucloxacillin-capsules-bp-500mg-a8f5c4ced4c1b810Pharma Surgeen2026-06-30T11:58:19.000ZClass 3 Medicines Recall: Flamingo Pharma UK Ltd, Flucloxacillin Capsules BP 500mg, EL(26)A/32https://www.pharmaradar360.com/article/fda-hits-praxis-with-3-month-delay-for-epilepsy-drug-verdict-e94a44884b558418Pharma Surgeen2026-06-30T11:57:19.000ZFDA hits Praxis with 3-month delay for epilepsy drug verdicthttps://www.pharmaradar360.com/article/delaware-court-throws-out-biotech-ipo-derivative-suit-b79956dafa01096fPharma Surgeen2026-06-30T11:55:46.000ZDelaware court throws out biotech IPO derivative suithttps://www.pharmaradar360.com/article/alexandre-detappe-recoit-un-financement-europeen-selectif-pour-potentialiser-l-i-9bb4086f4ba81278Pharma Surgeen2026-06-30T11:41:57.000ZAlexandre Detappe reçoit un financement européen sélectif pour potentialiser l’immunothérapiehttps://www.pharmaradar360.com/article/concursos-presidencia-9d33c23ab6cdcd9ePharma Surgeen2026-06-30T11:40:12.000ZConcursos Presidenciahttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-unicycive-s-drug-to-treat-elevated-phosphate-levels-i-c8ddcf390f2a0226Pharma Surgeen2026-06-30T11:38:40.000ZUS FDA declines to approve Unicycive’s drug to treat elevated phosphate levels in dialysis patientshttps://www.pharmaradar360.com/article/cook-medical-beat-the-heat-5k-named-2026-rrca-championship-race-23ba7bda460162f6Pharma Surgeen2026-06-30T11:34:37.000ZCook Medical Beat the Heat 5K Named 2026 RRCA Championship Racehttps://www.pharmaradar360.com/article/new-danish-biotech-company-aims-to-turn-new-brain-biology-into-business-now-we-l-89f36a8344c26cefPharma Surgeen2026-06-30T11:33:54.000ZNew Danish biotech company aims to turn new brain biology into business: "Now we'll see if we can make it fly"https://www.pharmaradar360.com/article/palvella-therapeutics-appoints-accomplished-rare-disease-biotech-executive-and-c-462381039591be28Pharma Surgeen2026-06-30T11:30:00.000ZPalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directorshttps://www.pharmaradar360.com/article/what-does-a-medieval-calf-look-like-in-mass-spectrometry-d1422e8d3ef2823bPharma Surgeen2026-06-30T11:26:30.000ZWhat does a medieval calf look like in mass spectrometry?https://www.pharmaradar360.com/article/unicycive-therapeutics-receives-complete-response-letter-from-fda-regarding-resu-25570acd687587e6Pharma Surgeen2026-06-30T11:22:14.000ZUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)https://www.pharmaradar360.com/article/mag-7-action-improves-but-biotech-keeps-delivering-the-real-wins-a902788400556c08Pharma Surgeen2026-06-30T11:21:00.000ZMag 7 Action Improves, But Biotech Keeps Delivering the Real Winshttps://www.pharmaradar360.com/article/criion-joachim-frank-prize-2026-awarded-to-cancer-researchers-in-freiburg-9cf1b40ba58793a8Pharma Surgeen2026-06-30T11:19:37.000ZCRIION Joachim Frank Prize 2026 awarded to cancer researchers in Freiburghttps://www.pharmaradar360.com/article/leveraging-sentiment-analysis-to-evaluate-clinical-outcome-assessments-a54fb6d4e24bbd93Pharma Surgeen2026-06-30T11:06:16.000ZLeveraging Sentiment Analysis to Evaluate Clinical Outcome Assessmentshttps://www.pharmaradar360.com/article/unicycive-s-kidney-drug-hits-fda-setback-as-label-talks-continue-f73eeb319f397fd2Pharma Surgeen2026-06-30T11:05:00.000ZUnicycive’s kidney drug hits FDA setback as label talks continuehttps://www.pharmaradar360.com/article/unicycive-therapeutics-receives-complete-response-letter-7588ba6eb03c7a80Pharma Surgeen2026-06-30T11:05:00.000ZUnicycive Therapeutics Receives Complete Response Letterhttps://www.pharmaradar360.com/article/rubin-observatory-begins-a-10-year-movie-of-the-changing-universe-27aa862e6d7a1c92Pharma Surgeen2026-06-30T11:00:00.000ZRubin observatory begins a 10-year movie of the changing universehttps://www.pharmaradar360.com/article/hamptons-heart-ball-raises-funds-to-fight-heart-disease-and-stroke-1bda0ea251fad4c6Pharma Surgeen2026-06-30T11:00:00.000ZHamptons Heart Ball raises funds to fight heart disease and strokehttps://www.pharmaradar360.com/article/bms-backed-beeline-putting-worker-bee-mentality-into-effect-with-126m-series-a-e-789264a8ed187ba2Pharma Surgeen2026-06-30T11:00:00.000ZBMS-backed Beeline 'putting worker bee mentality into effect' with $126M series A extensionhttps://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-7284d62d5e1b037cPharma Surgeen2026-06-30T11:00:00.000ZBiotech ETF (BBC) Touches a New 52-Week Highhttps://www.pharmaradar360.com/article/financialcontent-sizzling-stocks-under-5-upc-any-nnbr-dcoy-target-ai-infrastruct-0b678f7207fd87aaPharma Surgeen2026-06-30T10:29:00.000ZFinancialContent - Sizzling Stocks Under $5: UPC, ANY, NNBR, DCOY Target AI Infrastructure, Data Centers, Pharmaceutical Innovation and Biotechnology Growthhttps://www.pharmaradar360.com/article/rats-cockroaches-rotting-food-fda-suspends-six-mumbai-eateries-in-hygiene-crackd-7a0523108a38b76fPharma Surgeen2026-06-30T10:25:23.000ZRats, cockroaches, rotting food: FDA suspends six Mumbai eateries in hygiene crackdownhttps://www.pharmaradar360.com/article/hazmat-situation-contained-at-keystone-research-and-pharmaceutical-in-cherry-hil-b2a76ad8f454691cPharma Surgeen2026-06-30T10:22:31.000ZHazmat situation contained at Keystone Research and Pharmaceutical in Cherry Hill, New Jerseyhttps://www.pharmaradar360.com/article/information-about-the-criminal-offence-committed-by-a-former-employee-of-the-uni-afeb1817cf8f5ce8Pharma Surgeen2026-06-30T10:21:00.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/india-s-first-homegrown-antibiotic-zaynich-gets-us-fda-approval-here-s-what-you-a4a279c939252c55Pharma Surgeen2026-06-30T10:14:27.000ZIndia's First Homegrown Antibiotic Zaynich Gets US FDA Approval; Here's What You Need To Know About The Drughttps://www.pharmaradar360.com/article/university-elections-2026-c3b78142c55dc9d4Pharma Surgeen2026-06-30T10:09:16.000ZUniversity Elections 2026https://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-c6d3203477fa551bPharma Surgeen2026-06-30T10:06:51.000ZBiotech ETF (BBC) Touches a New 52-Week Highhttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-relonchem-limited-gabapentin-relonchem-50m-061aa46b22f7032ePharma Surgeen2026-06-30T10:06:09.000ZClass 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31https://www.pharmaradar360.com/article/india-s-first-homegrown-antibiotic-zaynich-gets-us-fda-approval-here-s-what-you-96748c3a7627e41fPharma Surgeen2026-06-30T10:05:58.000ZIndia's First Homegrown Antibiotic Zaynich Gets US FDA Approval; Here's What You Need To Know About The Drughttps://www.pharmaradar360.com/article/obesity-drugs-after-the-gold-rush-ddb815cdc0f5b235Pharma Surgeen2026-06-30T10:03:58.000ZObesity drugs after the gold rushhttps://www.pharmaradar360.com/article/public-asked-to-nominate-their-local-nhs-heroes-for-nhsggc-people-s-choice-award-3fa1d7d1ae66731ePharma Surgeen2026-06-30T10:00:55.000ZPublic asked to nominate their local NHS heroes for NHSGGC People’s Choice Awardhttps://www.pharmaradar360.com/article/quadram-institute-announces-major-european-research-milestone-in-myalgic-encepha-d80c8db9eb62ae80Pharma Surgeen2026-06-30T09:48:17.000ZQuadram Institute Announces Major European Research Milestone in Myalgic Encephalomyelitis (ME)https://www.pharmaradar360.com/article/from-early-promise-to-pivotal-success-operationalizing-rlt-trials-for-scale-oran-bda1b6599f00d4b5Pharma Surgeen2026-06-30T09:46:58.000ZFrom Early Promise to Pivotal Success: Operationalizing RLT Trials for Scale [Orano Med + PSI at TRP Summit]https://www.pharmaradar360.com/article/can-hansoh-pharmaceutical-monetize-its-expanding-drug-portfolio-79cc0770efd49919Pharma Surgeen2026-06-30T09:37:45.000ZCan Hansoh Pharmaceutical Monetize Its Expanding Drug Portfolio?https://www.pharmaradar360.com/article/mass-biotech-ipo-proceeds-near-3-2b-close-in-on-pandemic-era-record-pace-4e0ff3c307f8cedcPharma Surgeen2026-06-30T09:37:00.000ZMass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pacehttps://www.pharmaradar360.com/article/salipro-biotech-announces-publication-in-nature-scientific-reports-on-expanding-179d6d88012b9ac4Pharma Surgeen2026-06-30T09:30:00.000ZSalipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteinshttps://www.pharmaradar360.com/article/a-new-injection-is-helping-people-with-copd-breathe-more-easily-df4f38795737c9eePharma Surgeen2026-06-30T09:24:50.000ZA new injection is helping people with COPD breathe more easilyhttps://www.pharmaradar360.com/article/den-ursachen-der-spina-bifida-auf-der-spur-da1088caa88f09f9Pharma Surgeen2026-06-30T09:14:16.000ZDen Ursachen der Spina bifida auf der Spurhttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-6616af9917829d3aPharma Surgeen2026-06-30T09:04:29.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/package-deals-in-the-pharmaceutical-industry-and-disclosure-uk-data-089383a666793338Pharma Surgeen2026-06-30T09:04:15.000ZPackage deals in the pharmaceutical industry and Disclosure UK datahttps://www.pharmaradar360.com/article/cells-boundaries-and-the-emergence-of-biological-order-6574a69fcb9fd82bPharma Surgeen2026-06-30T09:01:56.000ZCells, boundaries, and the emergence of biological orderhttps://www.pharmaradar360.com/article/kff-polling-on-health-information-and-trust-49822802bc264ee0Pharma Surgeen2026-06-30T09:00:13.000ZKFF Polling on Health Information and Trusthttps://www.pharmaradar360.com/article/kff-tracking-poll-on-health-information-and-trust-update-on-common-vaccine-myths-3560ca42cc15dfa7Pharma Surgeen2026-06-30T09:00:00.000ZKFF Tracking Poll on Health Information and Trust: Update on Common Vaccine Mythshttps://www.pharmaradar360.com/article/poll-people-without-a-trusted-health-care-provider-are-more-likely-to-endorse-va-dc02770fbec8b2e9Pharma Surgeen2026-06-30T09:00:00.000ZPoll: People Without a Trusted Health Care Provider Are More Likely to Endorse Vaccine Myths, As Are Those Who Often Use Social Media or AI for Health Informationhttps://www.pharmaradar360.com/article/everyone-is-the-main-character-in-their-own-story-at-maria-pepe-42badf493c5c3d11Pharma Surgeen2026-06-30T09:00:00.000ZEveryone is the main character in their own story at Maria & Pepehttps://www.pharmaradar360.com/article/next-generation-scans-now-helping-patients-at-royal-brompton-ae2bb99b8e1c48a9Pharma Surgeen2026-06-30T08:56:08.000ZNext-generation scans now helping patients at Royal Bromptonhttps://www.pharmaradar360.com/article/crg-signs-mou-with-shenzhen-institutes-smart-and-szbl-51525d4463d0197ePharma Surgeen2026-06-30T08:54:52.000ZCRG signs MoU with Shenzhen institutes SMART and SZBLhttps://www.pharmaradar360.com/article/lonza-usa-eyes-1-billion-clermont-county-biotech-plant-ohio-b5fa3a5c00ce46a8Pharma Surgeen2026-06-30T08:47:41.000ZLonza USA Eyes $1 Billion Clermont County Biotech Plant, Ohiohttps://www.pharmaradar360.com/article/hlth-europe-2026-healthcare-implementation-key-amid-european-innovation-rush-ff24547b5df33046Pharma Surgeen2026-06-30T08:44:47.000ZHLTH Europe 2026: Healthcare implementation key amid European innovation rushhttps://www.pharmaradar360.com/article/ukhsa-evaluation-strategy-b5835dc077e447e2Pharma Surgeen2026-06-30T08:30:00.000ZUKHSA Evaluation Strategyhttps://www.pharmaradar360.com/article/russia-and-cuba-set-up-first-joint-pharmaceutical-venture-36ea979131b17e4ePharma Surgeen2026-06-30T08:18:22.000ZRussia and Cuba set up first joint pharmaceutical venturehttps://www.pharmaradar360.com/article/price-to-book-forward-of-proto-script-pharmaceutical-corp-otc-pscr-0a2585d8b9a61803Pharma Surgeen2026-06-30T08:03:27.000ZPrice to book forward of PROTO SCRIPT PHARMACEUTICAL CORP – OTC:PSCRhttps://www.pharmaradar360.com/article/pfas-in-medicines-can-often-be-replaced-with-alternatives-ffc499c6277bf675Pharma Surgeen2026-06-30T08:01:52.000ZPFAS in medicines can often be replaced with alternativeshttps://www.pharmaradar360.com/article/fda-a72cac3827eb8431Pharma Surgeen2026-06-30T08:00:00.000Zエンスプリングに関するロシュ社の発表について（甲状腺眼症に対する申請が米国FDAに受理）https://www.pharmaradar360.com/article/roche-s-announcement-regarding-enspryng-fda-accepts-application-for-thyroid-eye-a4caf8c0a146634fPharma Surgeen2026-06-30T08:00:00.000ZRoche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)https://www.pharmaradar360.com/article/wuxi-biologics-receives-brazil-anvisa-gmp-certification-to-enable-global-commerc-5676096b2de3dda1Pharma Surgeen2026-06-30T07:58:10.000ZWuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapyhttps://www.pharmaradar360.com/article/australians-voice-outlook-and-rising-impact-of-wicked-problems-c300d273181a016bPharma Surgeen2026-06-30T07:22:49.000ZAustralians voice outlook and rising impact of wicked problemshttps://www.pharmaradar360.com/article/scientists-may-have-finally-found-how-alzheimer-s-spreads-through-the-brain-6d1a241ed4b60426Pharma Surgeen2026-06-30T07:21:06.000ZScientists may have finally found how Alzheimer's spreads through the brainhttps://www.pharmaradar360.com/article/global-biopharmaceutical-ceos-response-to-reforms-introduced-in-germany-dd88dba49d4267f6Pharma Surgeen2026-06-30T07:20:42.000ZGlobal biopharmaceutical CEOs response to reforms introduced in Germanyhttps://www.pharmaradar360.com/article/weather-stations-measure-record-breaking-temperatures-in-freiburg-city-6ca2a853a369577dPharma Surgeen2026-06-30T07:16:17.000ZWeather stations measure record-breaking temperatures in Freiburg Cityhttps://www.pharmaradar360.com/article/french-biotech-stock-soars-40-after-new-data-on-experimental-medicine-2a6d2ca2fc700843Pharma Surgeen2026-06-30T07:13:05.000ZFrench biotech stock soars 40% after new data on experimental medicinehttps://www.pharmaradar360.com/article/from-wound-care-to-prevention-keeping-people-with-diabetes-on-their-feet-f3155102c2f313edPharma Surgeen2026-06-30T07:12:28.000ZFrom wound care to prevention: Keeping people with diabetes on their feethttps://www.pharmaradar360.com/article/adragos-signs-agreement-with-towa-pharmaceutical-to-supply-off-patent-medicines-b2c995bf1e31617dPharma Surgeen2026-06-30T07:10:35.000ZAdragos signs agreement with Towa Pharmaceutical to supply off-patent medicineshttps://www.pharmaradar360.com/article/joint-statement-on-warning-to-pharmacists-about-diverted-hiv-medicines-being-sol-40552ace77c6c496Pharma Surgeen2026-06-30T07:03:12.000ZJoint Statement on Warning to Pharmacists About Diverted HIV Medicines Being Sold on Online Pharmacy-to-Pharmacy Platformshttps://www.pharmaradar360.com/article/first-aid-biotech-battle-moves-to-parliament-2ddd4b81b60b6ad5Pharma Surgeen2026-06-30T07:00:31.000ZFIRST AID: Biotech battle moves to Parliamenthttps://www.pharmaradar360.com/article/regents-approve-interim-structure-for-nebraska-medicine-governance-ed298b81ec6880cdPharma Surgeen2026-06-30T07:00:00.000ZRegents approve interim structure for Nebraska Medicine governancehttps://www.pharmaradar360.com/article/rassegnastampa-il-cervello-non-va-in-vacanza-ma-il-caldo-lo-mette-a-dura-prova-m-5947a47f6bc6b7ddPharma Surgeen2026-06-30T07:00:00.000Z#RASSEGNASTAMPA. Il cervello non va in vacanza (ma il caldo lo mette a dura prova). Marco Locatelli a Radio 24https://www.pharmaradar360.com/article/teamwork-in-academia-through-teamwork-we-get-inspiration-and-innovation-going-6f2a02789fc1a098Pharma Surgeen2026-06-30T07:00:00.000ZTeamwork in academia: “through teamwork, we get inspiration and innovation going.”https://www.pharmaradar360.com/article/smartwatch-study-finds-older-adults-can-accurately-judge-their-mental-sharpness-29857e03714e2410Pharma Surgeen2026-06-30T07:00:00.000ZSmartwatch study finds older adults can accurately judge their mental sharpness in daily lifehttps://www.pharmaradar360.com/article/emergency-medicine-physician-angela-jarman-wins-award-from-national-organization-f122c72cf43c2622Pharma Surgeen2026-06-30T07:00:00.000ZEmergency medicine physician Angela Jarman wins award from national organizationhttps://www.pharmaradar360.com/article/towards-an-eu-clinical-trials-competitiveness-initiative-restoring-europe-s-edge-e192bcdc7d5ef7d4Pharma Surgeen2026-06-30T06:58:21.000ZTowards an EU clinical trials competitiveness initiative: restoring Europe's edgehttps://www.pharmaradar360.com/article/unmc-team-studying-neuroinflammation-in-people-with-hiv-acc9678396e9d72dPharma Surgeen2026-06-30T06:58:00.000ZUNMC team studying neuroinflammation in people with HIVhttps://www.pharmaradar360.com/article/portions-of-mcgoogan-library-to-reopen-tuesday-d4b9fc7dd829cbd6Pharma Surgeen2026-06-30T06:56:00.000ZPortions of McGoogan Library to reopen Tuesdayhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-takeda-pharmaceutical-co-ltd-tse-4502-e63edabf81de1f8fPharma Surgeen2026-06-30T06:55:40.000ZEnterprise value to revenue forward of Takeda Pharmaceutical Co. Ltd. – TSE:4502https://www.pharmaradar360.com/article/med-center-shuttle-out-of-service-this-friday-6b65454b33aca243Pharma Surgeen2026-06-30T06:54:00.000ZMed center shuttle out of service this Fridayhttps://www.pharmaradar360.com/article/genmab-s-epcoritamab-plus-lenalidomide-meets-phase-3-goal-in-relapsed-dlbcl-41c406ee2951ced8Pharma Surgeen2026-06-30T06:53:10.000ZGenmab’s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCLhttps://www.pharmaradar360.com/article/leeds-research-and-innovation-annual-conference-2026-8eb222d30fa96b56Pharma Surgeen2026-06-30T06:33:41.000ZLeeds Research and Innovation Annual Conference 2026https://www.pharmaradar360.com/article/number-of-shares-and-votes-in-active-biotech-eada6aa6eb651f00Pharma Surgeen2026-06-30T06:31:16.000ZNumber of shares and votes in Active Biotechhttps://www.pharmaradar360.com/article/ai-llm-62e238dcb1d9cb78Pharma Surgeen2026-06-30T06:30:00.000Z治験候補患者抽出の精度向上・効率化に向け、リアルワールドデータと生成AI（LLM）を用いた共同研究を開始https://www.pharmaradar360.com/article/launch-of-joint-research-using-real-world-data-and-generative-ai-llm-to-improve-b9ae34b323f26797Pharma Surgeen2026-06-30T06:30:00.000ZLaunch of Joint Research Using Real-World Data and Generative AI (LLM) to Improve the Accuracy and Efficiency of Identifying Candidate Patients for Clinical Trialshttps://www.pharmaradar360.com/article/number-of-shares-and-votes-in-active-biotech-da30b5412c865194Pharma Surgeen2026-06-30T06:30:00.000ZNumber of shares and votes in Active Biotechhttps://www.pharmaradar360.com/article/scientists-say-creatine-may-help-fight-depression-30cc8b49b58d1927Pharma Surgeen2026-06-30T06:28:57.000ZScientists say creatine may help fight depressionhttps://www.pharmaradar360.com/article/fran-forrad-till-livsviktig-resurs-nu-rustas-skyddsrummen-upp-58d3252c009ab317Pharma Surgeen2026-06-30T06:20:22.000ZFrån förråd till livsviktig resurs – nu rustas skyddsrummen upphttps://www.pharmaradar360.com/article/rethinking-clinical-outcome-assessments-what-sentiment-analysis-reveals-about-pa-fb6b91630e003acbPharma Surgeen2026-06-30T05:56:57.000ZRethinking Clinical Outcome Assessments: What Sentiment Analysis Reveals About Patient Feedbackhttps://www.pharmaradar360.com/article/rats-cockroaches-found-in-6-mumbai-restaurants-fda-suspends-licences-101645a4d3a04f0ePharma Surgeen2026-06-30T05:50:57.000ZRats, cockroaches found in 6 Mumbai restaurants, FDA suspends licenceshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hatinh-pharmaceutical-joint-stock-co-upcom-39ee08754a962fe7Pharma Surgeen2026-06-30T05:35:15.000ZEnterprise value to EBITDA forward of HaTinh Pharmaceutical Joint Stock Co – UPCOM:HDPhttps://www.pharmaradar360.com/article/mumbai-food-dept-finds-rats-cockroaches-expired-food-at-six-eateries-located-in-795eb7cf008e9232Pharma Surgeen2026-06-30T05:34:00.000ZMumbai food dept finds rats, cockroaches, expired food at six eateries located in Nariman Point, Borivali,https://www.pharmaradar360.com/article/price-to-earnings-forward-of-hatinh-pharmaceutical-joint-stock-co-upcom-hdp-e2bf134b43190da2Pharma Surgeen2026-06-30T05:32:51.000ZPrice to earnings forward of HaTinh Pharmaceutical Joint Stock Co – UPCOM:HDPhttps://www.pharmaradar360.com/article/2027-step-out-walk-baltimore-e157ac86bc9d93fbPharma Surgeen2026-06-30T05:31:21.000Z2027 Step Out® Walk: Baltimorehttps://www.pharmaradar360.com/article/price-to-book-forward-of-zhejiang-wolwo-bio-pharmaceutical-co-ltd-class-a-szse-3-c3e852638b7dbf71Pharma Surgeen2026-06-30T05:14:22.000ZPrice to book forward of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A – SZSE:300357https://www.pharmaradar360.com/article/fda-grants-priority-review-to-roche-s-enspryng-the-first-and-only-at-home-subcut-ebaed64621cc9dd8Pharma Surgeen2026-06-30T05:00:00.000ZFDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)https://www.pharmaradar360.com/article/price-to-book-forward-of-hatinh-pharmaceutical-joint-stock-co-upcom-hdp-87966735aee9471ePharma Surgeen2026-06-30T04:59:25.000ZPrice to book forward of HaTinh Pharmaceutical Joint Stock Co – UPCOM:HDPhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-shanghai-fosun-pharmaceutical-group-co-ltd-class-a-sse-9c712edc31923bf0Pharma Surgeen2026-06-30T04:50:19.000ZPrice to sales forward of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A – SSE:600196https://www.pharmaradar360.com/article/price-to-earnings-forward-of-shanghai-fosun-pharmaceutical-group-co-ltd-class-a-4e339d92ed33a459Pharma Surgeen2026-06-30T04:48:29.000ZPrice to earnings forward of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A – SSE:600196https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-burning-rock-biotech-ltd-sponsored-adr-dus-6-060b041648c696ecPharma Surgeen2026-06-30T04:37:28.000ZEnterprise value to EBIT forward of Burning Rock Biotech Ltd. Sponsored ADR – DUS:6BU0https://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-5f4b015ba4b1f6f6Pharma Surgeen2026-06-30T03:30:50.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/hong-kong-draws-royalties-giant-as-mainland-china-biotech-licensing-heats-up-abf08a7d3768f156Pharma Surgeen2026-06-30T03:00:12.000ZHong Kong draws royalties giant as mainland China biotech licensing heats uphttps://www.pharmaradar360.com/article/consolidated-financial-statements-for-years-ended-march-31-2026-and-2025-f11b767573b748abPharma Surgeen2026-06-30T03:00:00.000ZConsolidated Financial Statements for Years ended March 31, 2026 and 2025https://www.pharmaradar360.com/article/anzen-revisions-of-precautions-cefcapene-pivoxil-hydrochloride-hydrate-etc-poste-0d804fa20c6b9ae8Pharma Surgeen2026-06-30T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Cefcapene Pivoxil Hydrochloride Hydrate, etc. postedhttps://www.pharmaradar360.com/article/anzen-pmda-alert-for-proper-use-of-drugs-serious-hypocarnitinemia-and-hypoglycae-118b6d6f33bb9cd3Pharma Surgeen2026-06-30T03:00:00.000Z[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) postedhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-susmed-app-for-insomnia-medcle-parti-07745d167fb2bb02Pharma Surgeen2026-06-30T03:00:00.000Z[SHINSA]English Translation of Review Report: SUSMED App for Insomnia Medcle (Partial Change Approval)https://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-ceo-disposes-shares-to-cover-rsu-tax-d8db950cc8066f7aPharma Surgeen2026-06-30T02:44:13.000ZLegend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU taxhttps://www.pharmaradar360.com/article/aci-s-13th-annual-summit-for-women-leaders-in-life-sciences-law-e86b7d799e8f3b06Pharma Surgeen2026-06-30T02:15:19.000ZACI’s 13th Annual Summit for Women Leaders in Life Sciences Lawhttps://www.pharmaradar360.com/article/does-recursion-rxrx-russell-value-index-lift-recast-its-ai-biotech-story-as-deep-13b29570161c0306Pharma Surgeen2026-06-30T02:13:41.000ZDoes Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value?https://www.pharmaradar360.com/article/evaluating-oral-btk-inhibitor-remibrutinib-in-phase-3-study-for-generalized-myas-0a3fb1b1502db443Pharma Surgeen2026-06-30T01:40:38.000ZEvaluating Oral BTK Inhibitor Remibrutinib in Phase 3 Study for Generalized Myasthenia Gravis: The RELIEVE Trialhttps://www.pharmaradar360.com/article/hesso-56-282eb311585a4000Pharma Surgeen2026-06-30T01:07:11.000Z広報誌「hesso（へっそ）」56号を発行しましたhttps://www.pharmaradar360.com/article/compound-pharmacies-are-outrunning-regulations-experts-want-tougher-oversight-a4d199120cadaea9Pharma Surgeen2026-06-30T01:03:50.000ZCompound pharmacies are outrunning regulations. Experts want tougher oversight.https://www.pharmaradar360.com/article/contribution-from-ownership-to-connection-what-bio-usa-says-about-the-next-50-ye-e842ea8e4e5cc0e5Pharma Surgeen2026-06-30T00:35:07.000Z[Contribution] From ownership to connection: What BIO USA says about the next 50 years of biotechhttps://www.pharmaradar360.com/article/abivax-reports-phase-3-ulcerative-colitis-trial-results-by-investing-com-18163fa9a33778f4Pharma Surgeen2026-06-30T00:14:16.000ZAbivax reports phase 3 ulcerative colitis trial results By Investing.comhttps://www.pharmaradar360.com/article/long-term-outcomes-of-adjuvant-metronomic-capecitabine-in-locoregionally-advance-890f648dbd6bc33fPharma Surgeen2026-06-30T00:00:00.000ZLong-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyhttps://www.pharmaradar360.com/article/connectomic-evidence-that-ordered-activity-drives-neuromuscular-network-formatio-043a1c7e99dde4daPharma Surgeen2026-06-30T00:00:00.000ZConnectomic evidence that ordered activity drives neuromuscular network formationhttps://www.pharmaradar360.com/article/author-correction-digital-avatar-therapy-for-distressing-voices-in-psychosis-the-c3af7c5537501514Pharma Surgeen2026-06-30T00:00:00.000ZAuthor Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trialhttps://www.pharmaradar360.com/article/clinical-decision-support-in-hematological-malignancies-using-a-case-grounded-ai-8a61282da4bf3b4ePharma Surgeen2026-06-30T00:00:00.000ZClinical decision support in hematological malignancies using a case-grounded AI agenthttps://www.pharmaradar360.com/article/multi-antigen-targeting-t-cells-in-pediatric-central-nervous-system-tumors-a-pha-821019a0b82180bePharma Surgeen2026-06-30T00:00:00.000ZMulti-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trialhttps://www.pharmaradar360.com/article/prime-editing-for-precise-genome-engineering-and-modulation-of-fungal-metabolism-166096d5ba74f905Pharma Surgeen2026-06-30T00:00:00.000ZPrime editing for precise genome engineering and modulation of fungal metabolismhttps://www.pharmaradar360.com/article/editor-s-pick-liberate-bio-d9dfa435c8c9ca49Pharma Surgeen2026-06-30T00:00:00.000ZEditor’s pick: Liberate Biohttps://www.pharmaradar360.com/article/editor-s-pick-trogenix-f6934e08bd97400ePharma Surgeen2026-06-30T00:00:00.000ZEditor’s pick: Trogenixhttps://www.pharmaradar360.com/article/enhanced-b-cell-priming-induces-broadly-neutralizing-hiv-1-apex-antibodies-0fbbcd7b83608188Pharma Surgeen2026-06-30T00:00:00.000ZEnhanced B cell priming induces broadly neutralizing HIV-1 apex antibodieshttps://www.pharmaradar360.com/article/vaccination-elicits-hiv-broadly-neutralizing-antibodies-in-primates-c2abac67dc7ce5e3Pharma Surgeen2026-06-30T00:00:00.000ZVaccination elicits HIV broadly neutralizing antibodies in primateshttps://www.pharmaradar360.com/article/retraction-note-nsd2-targeting-reverses-plasticity-and-drug-resistance-in-prosta-44b1f4496033e91dPharma Surgeen2026-06-30T00:00:00.000ZRetraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancerhttps://www.pharmaradar360.com/article/agents-amie-and-mira-advance-medical-ai-capabilities-59df51e06aef4fc6Pharma Surgeen2026-06-30T00:00:00.000ZAgents AMIE and MIRA advance medical AI capabilitieshttps://www.pharmaradar360.com/article/ebola-preparedness-must-start-with-ecosystems-and-before-humans-show-symptoms-36b973f5ccc0f341Pharma Surgeen2026-06-30T00:00:00.000ZEbola preparedness must start with ecosystems and before humans show symptomshttps://www.pharmaradar360.com/article/ai-tools-can-speed-up-thinking-but-evidence-still-comes-from-the-lab-bench-cbf0002c6aa8eac8Pharma Surgeen2026-06-30T00:00:00.000ZAI tools can speed up thinking, but evidence still comes from the lab benchhttps://www.pharmaradar360.com/article/child-online-safety-needs-more-than-social-media-bans-a01b6ba517a60e71Pharma Surgeen2026-06-30T00:00:00.000ZChild online safety needs more than social-media banshttps://www.pharmaradar360.com/article/can-rwanda-sustain-its-rise-in-science-and-technology-here-s-what-can-help-fba21fa52e2eece5Pharma Surgeen2026-06-30T00:00:00.000ZCan Rwanda sustain its rise in science and technology? Here’s what can helphttps://www.pharmaradar360.com/article/coffee-is-under-threat-how-scientists-are-fighting-to-save-it-from-extinction-59d95c6e1b94952aPharma Surgeen2026-06-30T00:00:00.000ZCoffee is under threat: how scientists are fighting to save it from extinctionhttps://www.pharmaradar360.com/article/ai-systems-devise-hypotheses-and-ways-to-test-them-e6c02c04612efbcdPharma Surgeen2026-06-30T00:00:00.000ZAI systems devise hypotheses and ways to test themhttps://www.pharmaradar360.com/article/early-television-set-impresses-nature-editors-but-will-it-catch-on-44f4f5b50b3bfbcbPharma Surgeen2026-06-30T00:00:00.000ZEarly television set impresses Nature editors — but will it catch on?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-da7e73ee023c2532Pharma Surgeen2026-06-30T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-4c37464e14ef7be1Pharma Surgeen2026-06-30T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-4ea220a4191a14f5Pharma Surgeen2026-06-30T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-968d33f0e4ddb018Pharma Surgeen2026-06-30T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-32aae66a7dca5accPharma Surgeen2026-06-30T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-d1d5cf4213f314f7Pharma Surgeen2026-06-30T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-19740c84cbca5d17Pharma Surgeen2026-06-30T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-d3738f0b72fbbcb2Pharma Surgeen2026-06-30T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-d90a30afbcc099ecPharma Surgeen2026-06-30T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-a1075cdc2077fffaPharma Surgeen2026-06-30T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-c7750e1d3eddd997Pharma Surgeen2026-06-30T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b9466d58512ea8bdPharma Surgeen2026-06-30T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-f0f74d9668cf10ddPharma Surgeen2026-06-30T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-431988b9d9fba7e5Pharma Surgeen2026-06-30T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/proposed-collection-30-day-comment-request-nih-information-collection-forms-to-s-dbef6a57b59d1ea8Pharma Surgeen2026-06-30T00:00:00.000ZProposed Collection; 30-Day Comment Request; NIH Information Collection Forms to Support the Genetic Testing Registry (OD)https://www.pharmaradar360.com/article/world-trade-center-health-program-petitions-024-042-046-047-051-056-058-and-067-2a108a668ae46fb9Pharma Surgeen2026-06-30T00:00:00.000ZWorld Trade Center Health Program; Petitions 024, 042, 046, 047, 051, 056, 058, and 067-Ischemic Heart Disease; Finding of Insufficient Evidencehttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-meeting-58c7a7655aee1fb9Pharma Surgeen2026-06-30T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Meetinghttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-united-states-pharmacopeial-conven-83e4e0cea83ddd7ePharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: United States Pharmacopeial Conventionhttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-veterans-pharmaceuticals-inc-29babdf696c52cd3Pharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: Veterans Pharmaceuticals, Inc.https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-veranova-l-p-4955174adf61e7adPharma Surgeen2026-06-30T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Veranova, L.P.https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-almac-clinical-services-incorp-acs-5a4dda278936ddf2Pharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-catalent-pharma-solutions-llc-e3ea0d45794fb6d2Pharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: Catalent Pharma Solutions, LLChttps://www.pharmaradar360.com/article/statement-of-organization-functions-and-delegations-of-authority-bfb15c501f69ceddPharma Surgeen2026-06-30T00:00:00.000ZStatement of Organization, Functions, and Delegations of Authorityhttps://www.pharmaradar360.com/article/medical-devices-anesthesiology-devices-classification-of-the-monitor-for-opioid-24ff44f3449b53dcPharma Surgeen2026-06-30T00:00:00.000ZMedical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenationhttps://www.pharmaradar360.com/article/medical-devices-general-and-plastic-surgery-devices-classification-of-the-skin-p-d8cab6002554198cPharma Surgeen2026-06-30T00:00:00.000ZMedical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosishttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-adoption-and-foster-care-a-c6163f61ec0d8f28Pharma Surgeen2026-06-30T00:00:00.000ZSubmission for Office of Management and Budget Review; Adoption and Foster Care Analysis and Reporting System (AFCARS)https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-87c5f79a1e2a8f5dPharma Surgeen2026-06-30T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-f438494877cbd5bdPharma Surgeen2026-06-30T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-d8e1f5e8cb357ffdPharma Surgeen2026-06-30T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/drug-label-update-loperamide-hydrochloride-34f527e2a863fad9Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: Loperamide Hydrochloridehttps://www.pharmaradar360.com/article/drug-label-update-nystatin-c4a3e9d3e9bda5e6Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: NYSTATINhttps://www.pharmaradar360.com/article/forskare-vid-cns-som-tilldelats-cimed-projektbidrag-for-2027-2029-2e803d9a4e4b9f48Pharma Surgeen2026-06-30T00:00:00.000ZForskare vid CNS som tilldelats CIMED projektbidrag för 2027-2029https://www.pharmaradar360.com/article/erc-proof-of-concept-anslag-till-emma-andersson-ska-leda-till-farre-forsoksdjur-b33467954f3ff73fPharma Surgeen2026-06-30T00:00:00.000ZERC Proof of Concept-anslag till Emma Andersson ska leda till färre försöksdjurhttps://www.pharmaradar360.com/article/adverse-events-after-same-day-covid-19-and-influenza-vaccination-versus-influenz-629d30c80f14db91Pharma Surgeen2026-06-30T00:00:00.000ZAdverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alonehttps://www.pharmaradar360.com/article/clinical-research-progress-of-acupuncture-in-the-treatment-of-post-stroke-should-9a61419ec700cb7dPharma Surgeen2026-06-30T00:00:00.000ZClinical Research Progress of Acupuncture in the Treatment of Post-Stroke Shoulder-Hand Syndromehttps://www.pharmaradar360.com/article/the-role-of-baseline-pao2-fio2-spo2-and-il-6-indicators-in-predicting-in-hospita-457ab042dce97808Pharma Surgeen2026-06-30T00:00:00.000ZThe role of baseline PaO2/FiO2, SpO2 and IL-6 indicators in predicting in-hospital mortality in ARDS patients: a retrospective cohort studyhttps://www.pharmaradar360.com/article/migration-rates-clinical-and-technical-success-for-fixated-compared-to-non-fixat-41f90b400d36f060Pharma Surgeen2026-06-30T00:00:00.000ZMigration Rates, Clinical and Technical Success for Fixated Compared to Non-Fixated Fully Covered Esophageal Self-Expandable Metal Stents (FCSEMS)https://www.pharmaradar360.com/article/alcoholism-research-a-narrative-review-f72aa655d568da71Pharma Surgeen2026-06-30T00:00:00.000ZAlcoholism Research: A Narrative Reviewhttps://www.pharmaradar360.com/article/clinical-evaluation-of-facial-soft-tissue-profile-using-octa-criteria-in-patient-d6a15fbca471dda0Pharma Surgeen2026-06-30T00:00:00.000ZClinical evaluation of facial soft-tissue profile using OCTA criteria in patients: A cross-sectional studyhttps://www.pharmaradar360.com/article/effect-of-silver-diamine-fluoride-versus-fluoride-varnish-in-arresting-early-chi-0f705ae3f5ff6e8aPharma Surgeen2026-06-30T00:00:00.000ZEffect of silver diamine fluoride versus fluoride varnish in arresting early childhood caries: A clinical studyhttps://www.pharmaradar360.com/article/clinical-and-lateral-cephalometric-evaluation-of-class-ii-elastic-therapy-in-ske-e7669a350dca3818Pharma Surgeen2026-06-30T00:00:00.000ZClinical and lateral cephalometric evaluation of class II elastic therapy in skeletal class II malocclusion cases indicated for fixed functional appliance: An in vivo studyhttps://www.pharmaradar360.com/article/dry-needling-versus-kinesiotaping-for-upper-trapezius-trigger-points-a-randomize-2adf6da9e360ab4bPharma Surgeen2026-06-30T00:00:00.000ZDry Needling Versus Kinesiotaping for Upper Trapezius Trigger Points: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/pilot-case-control-study-of-mthfr-c677t-and-mtra2756g-polymorphisms-among-alcoho-ac23fea50c5c4a16Pharma Surgeen2026-06-30T00:00:00.000ZPILOT CASE–CONTROL STUDY OF MTHFR C677T AND MTRA2756G POLYMORPHISMS AMONG ALCOHOL/ TOBACCO USERS IN EASTERN UTTAR PRADESH, INDIA (N = 200)https://www.pharmaradar360.com/article/statistical-optimization-of-amylase-production-by-bacillus-wiedmannii-sppu-4-usi-f3ba7846b3833a9ePharma Surgeen2026-06-30T00:00:00.000ZSTATISTICAL OPTIMIZATION OF AMYLASE PRODUCTION BY BACILLUS WIEDMANNII SPPU 4 USING AGRO-INDUSTRIAL WASTES VIA PLACKETT-BURMAN AND BOX-BEHNKEN DESIGNShttps://www.pharmaradar360.com/article/the-diverse-clinical-presentation-of-mycoplasma-pneumoniae-and-role-of-biofire-f-f4b449c392da71f1Pharma Surgeen2026-06-30T00:00:00.000ZThe Diverse Clinical Presentation of Mycoplasma pneumoniae and Role of BioFire FilmArray Pneumonia Plus Panel: A Case Serieshttps://www.pharmaradar360.com/article/leveraging-statistical-and-machine-learning-techniques-to-enhance-clinical-decis-232629324d8e4f80Pharma Surgeen2026-06-30T00:00:00.000ZLeveraging Statistical and Machine Learning Techniques to Enhance Clinical Decision Support for PID Diagnosishttps://www.pharmaradar360.com/article/ai-enabled-diagnostics-treatment-planning-and-clinical-decision-634d27ef80ddae4aPharma Surgeen2026-06-30T00:00:00.000ZAI-Enabled Diagnostics, Treatment Planning, and Clinical Decisionhttps://www.pharmaradar360.com/article/fuzzy-neural-framework-for-clinical-safety-evaluation-of-medical-large-language-a4b05e443a7ab1b5Pharma Surgeen2026-06-30T00:00:00.000ZFuzzy Neural Framework for Clinical Safety Evaluation of Medical Large Language Modelshttps://www.pharmaradar360.com/article/boron-neutron-capture-therapy-for-recurrent-pediatric-sialoblastoma-the-first-cl-f2b6238e758d6d17Pharma Surgeen2026-06-30T00:00:00.000ZBoron neutron capture therapy for recurrent pediatric sialoblastoma: the first clinical experience and dosimetric considerations for skeletal safety with 4-year follow-uphttps://www.pharmaradar360.com/article/the-use-of-antihypertensive-drugs-in-pre-dialysis-chronic-kidney-disease-patient-449737fe248ec59aPharma Surgeen2026-06-30T00:00:00.000ZThe Use of Antihypertensive Drugs in Pre-Dialysis Chronic Kidney Disease Patientshttps://www.pharmaradar360.com/article/efficacy-of-escin-combined-with-micronized-purified-flavonoid-fraction-in-contro-836aefbcd61b61c8Pharma Surgeen2026-06-30T00:00:00.000ZEfficacy of escin combined with micronized purified flavonoid fraction in controlling bleeding and preventing recurrence of acute internal hemorrhoids: a randomized controlled trialhttps://www.pharmaradar360.com/article/new-perspectives-on-cutaneous-and-sexually-transmitted-infections-clinical-epide-268bcc399dcc1cc2Pharma Surgeen2026-06-30T00:00:00.000ZNew Perspectives on Cutaneous and Sexually Transmitted Infections: Clinical, Epidemiological, and Therapeutic Updateshttps://www.pharmaradar360.com/article/from-migration-to-emergency-a-systematic-review-of-acute-presentations-following-5931acac4cd6707bPharma Surgeen2026-06-30T00:00:00.000ZFrom Migration to Emergency: A Systematic Review of Acute Presentations Following Late Esophageal Stent Migrationhttps://www.pharmaradar360.com/article/saferx-a-canonical-pharmaceutical-knowledge-integration-framework-for-multimodal-953230d40d3d2dd6Pharma Surgeen2026-06-30T00:00:00.000ZSafeRx: A Canonical Pharmaceutical Knowledge Integration Framework for Multimodal Medication Safetyhttps://www.pharmaradar360.com/article/cognitive-affective-network-structure-in-adolescents-with-non-suicidal-self-inju-3a34ecbf0e972976Pharma Surgeen2026-06-30T00:00:00.000ZCognitive-affective network structure in adolescents with non-suicidal self-injury: implications for clinical interventionhttps://www.pharmaradar360.com/article/lung-cancer-organoids-for-functional-precision-oncology-from-disease-modeling-to-15e5f3a927ad1d43Pharma Surgeen2026-06-30T00:00:00.000ZLung cancer organoids for functional precision oncology: from disease modeling to clinical decision supporthttps://www.pharmaradar360.com/article/editorial-pharmaceutical-care-and-wellness-of-diabetes-8ab5f1998fada15bPharma Surgeen2026-06-30T00:00:00.000ZEditorial: Pharmaceutical care and wellness of diabeteshttps://www.pharmaradar360.com/article/long-term-stability-of-maxillary-protraction-in-severe-class-iii-cases-distracti-3caf955dd54d61fbPharma Surgeen2026-06-30T00:00:00.000ZLong-Term Stability of Maxillary Protraction in Severe Class III Cases: Distraction Osteogenesis vs. Prolonged Facemask Usehttps://www.pharmaradar360.com/article/clinical-case-of-treatment-of-a-patient-with-a-gunshot-wound-and-a-massive-osteo-78bb14d1493df41fPharma Surgeen2026-06-30T00:00:00.000ZClinical case of treatment of a patient with a gunshot wound and a massive osteo-soft tissue defect of the calcaneal regionhttps://www.pharmaradar360.com/article/1414417feb25f2e4Pharma Surgeen2026-06-30T00:00:00.000ZДинамика клинического состояния глаза и показателей клеточного и гуморального иммунитета у больных иридоциклитом под влиянием противовирусного препарата аллокин альфаhttps://www.pharmaradar360.com/article/assessment-of-health-related-quality-of-life-and-drug-related-problems-in-cardio-dd46397e1f288a6fPharma Surgeen2026-06-30T00:00:00.000ZAssessment of Health-Related Quality of Life and Drug-Related Problems In Cardiometabolic Patients In A Tertiary Care Hospital.https://www.pharmaradar360.com/article/comparative-evaluation-of-fetomaternal-outcome-in-gestational-thrombocytopenia-w-73f59122cb0b0198Pharma Surgeen2026-06-30T00:00:00.000ZComparative Evaluation of Fetomaternal Outcome in Gestational Thrombocytopenia with Thrombocytopenia Due to Hypertensive Disorders of Pregnancyhttps://www.pharmaradar360.com/article/long-term-clinical-outcomes-of-radiofrequency-ablation-for-pathologically-diagno-1fb5280917bba4acPharma Surgeen2026-06-30T00:00:00.000ZLong-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experiencehttps://www.pharmaradar360.com/article/transnasal-humidified-rapid-insufflation-ventilatory-exchange-in-preoperative-hy-18b6136ecd91c2e4Pharma Surgeen2026-06-30T00:00:00.000ZTransnasal Humidified Rapid-Insufflation Ventilatory Exchange in Preoperative Hypoxemic Patients During General Anesthesia Induction and Recovery: A Prospective Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-practice-guideline-recommendations-for-orthopedic-surgical-management-o-4a1b0b6924126505Pharma Surgeen2026-06-30T00:00:00.000ZClinical practice guideline recommendations for orthopedic surgical management of traumatic hip fractures: a systematic reviewhttps://www.pharmaradar360.com/article/evaluation-of-admission-level-clinical-laboratory-and-vascular-imaging-predictor-19e65d974bb4785ePharma Surgeen2026-06-30T00:00:00.000ZEvaluation of admission-level clinical, laboratory, and vascular imaging predictors of prolonged length of stay in acute ischemic strokehttps://www.pharmaradar360.com/article/geriatric-case-report-presenting-an-alzheimer-s-disease-patient-with-polypharmac-a72c110235825da8Pharma Surgeen2026-06-30T00:00:00.000ZGeriatric Case Report Presenting an Alzheimer’s Disease Patient with Polypharmacy Resulting in Significant Drug-Drug Interactionhttps://www.pharmaradar360.com/article/a-study-on-the-block-size-and-response-variables-determination-of-mbsd-in-the-mi-e821434bf523d773Pharma Surgeen2026-06-30T00:00:00.000ZA Study on the Block Size and Response Variables Determination of MBSD in the Mixing Processhttps://www.pharmaradar360.com/article/comparative-review-of-reimbursement-and-payment-models-for-gene-therapies-and-th-fe86c726b6e4aa4dPharma Surgeen2026-06-30T00:00:00.000ZComparative Review of Reimbursement and Payment Models for Gene Therapies and Their Policy Implicationshttps://www.pharmaradar360.com/article/renal-dysfunction-as-a-marker-of-adverse-outcomes-in-early-sepsis-in-the-emergen-ddab46eeffb3bac2Pharma Surgeen2026-06-30T00:00:00.000ZRenal dysfunction as a marker of adverse outcomes in early sepsis in the emergency departmenthttps://www.pharmaradar360.com/article/the-most-common-airway-foreign-bodies-removed-with-an-anti-choking-suction-devic-64d9c5837da2e1d1Pharma Surgeen2026-06-30T00:00:00.000ZThe most common airway foreign bodies removed with an anti-choking suction device: a descriptive retrospective studyhttps://www.pharmaradar360.com/article/recommendations-for-optimizing-the-use-of-dysmorphic-red-blood-cell-counts-in-th-149cb0b431125542Pharma Surgeen2026-06-30T00:00:00.000ZRecommendations for optimizing the use of dysmorphic red blood cell counts in the clinical laboratoryhttps://www.pharmaradar360.com/article/adjunctive-effects-of-combined-lacticaseibacillus-rhamnosus-dm163-and-lactobacil-dfc2b34a1c7e0c1cPharma Surgeen2026-06-30T00:00:00.000ZAdjunctive effects of combined Lacticaseibacillus rhamnosus DM163 and Lactobacillus plantarum DSR920 following scaling and root planing in patients with mild gingivitis: a randomized, double-blind pilot clinical trialhttps://www.pharmaradar360.com/article/oral-hygiene-behaviors-and-perceptions-of-tooth-gem-wearers-focusing-on-oral-hyg-8ec4583d5a3d468cPharma Surgeen2026-06-30T00:00:00.000ZOral Hygiene Behaviors and Perceptions of Tooth Gem Wearers: Focusing on Oral Hygiene Care Educational Experiencehttps://www.pharmaradar360.com/article/associations-between-tongue-coating-biofluorescence-and-oral-health-behaviors-in-06c34919ee02a9c9Pharma Surgeen2026-06-30T00:00:00.000ZAssociations between Tongue-Coating Biofluorescence and Oral Health Behaviors in Dental Hygiene Studentshttps://www.pharmaradar360.com/article/medical-devices-used-in-cystic-fibrosis-ba1e8def90838492Pharma Surgeen2026-06-30T00:00:00.000ZMedical Devices Used in Cystic Fibrosishttps://www.pharmaradar360.com/article/drug-penetration-in-solid-tumors-influence-of-drug-size-and-capillary-architectu-74a519e1509681fdPharma Surgeen2026-06-30T00:00:00.000ZDrug penetration in solid tumors: influence of drug size and capillary architecturehttps://www.pharmaradar360.com/article/cross-sectional-and-longitudinal-associations-of-activity-diversity-with-physica-0b86b09829539f0ePharma Surgeen2026-06-30T00:00:00.000ZCross-sectional and longitudinal associations of activity diversity with physical function in community-dwelling older adultshttps://www.pharmaradar360.com/article/exploring-scolymus-hispanicus-l-leaves-as-a-source-of-natural-therapeutics-nutri-b9b7fd7b8cdda33dPharma Surgeen2026-06-30T00:00:00.000ZExploring Scolymus hispanicus L. leaves as a source of natural therapeutics: nutritional, phytochemical, and pharmacological evaluationshttps://www.pharmaradar360.com/article/nct07676812-the-effect-of-animation-video-and-training-booklet-designed-on-breas-defc2a7a2a3ab55aPharma Surgeen2026-06-30T00:00:00.000ZNCT07676812: The Effect of Animation Video and Training Booklet Designed on Breast Cancerhttps://www.pharmaradar360.com/article/nct07676773-evaluate-the-effect-of-remote-exercise-intervention-on-blood-glucose-8ade779ffd6e12cfPharma Surgeen2026-06-30T00:00:00.000ZNCT07676773: Evaluate the Effect of Remote Exercise Intervention on Blood Glucose Control and Physical Fitness in T2DM Patientshttps://www.pharmaradar360.com/article/nct07676747-ralation-between-cardiorespiratory-fitness-and-mean-corrected-intrao-db2a5b95f9ef427cPharma Surgeen2026-06-30T00:00:00.000ZNCT07676747: Ralation Between Cardiorespiratory Fitness and Mean Corrected Intraocular Pressurehttps://www.pharmaradar360.com/article/nct07676318-large-language-models-for-dental-radiology-report-generation-from-st-4d8b749ffb227720Pharma Surgeen2026-06-30T00:00:00.000ZNCT07676318: Large Language Models for Dental Radiology Report Generation From Structured Textual Datahttps://www.pharmaradar360.com/article/nct07675564-impact-of-gender-identity-on-dentists-clinical-decision-making-772e7840f4a46049Pharma Surgeen2026-06-30T00:00:00.000ZNCT07675564: Impact of Gender Identity on Dentists' Clinical Decision-Makinghttps://www.pharmaradar360.com/article/nct07675304-evaluation-of-the-effectiveness-and-safety-of-mesotherapy-in-the-tre-51ba89bd329d7274Pharma Surgeen2026-06-30T00:00:00.000ZNCT07675304: Evaluation of the Effectiveness and Safety of Mesotherapy in the Treatment of Chronic Low Back Pain Syndromehttps://www.pharmaradar360.com/article/nct07675252-efficacy-and-safety-of-fluticasone-propionate-nebulized-suspension-f-3a8b0d8869d81aadPharma Surgeen2026-06-30T00:00:00.000ZNCT07675252: Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Monthshttps://www.pharmaradar360.com/article/nct07674940-a-trial-to-assess-tev-56286-at-different-doses-in-healthy-participan-7206aaeca73b2d3ePharma Surgeen2026-06-30T00:00:00.000ZNCT07674940: A Trial to Assess TEV-56286 at Different Doses in Healthy Participantshttps://www.pharmaradar360.com/article/nct07672002-cuidar-me-a-web-based-psychological-intervention-for-peri-menopausal-fd8375eb2be08856Pharma Surgeen2026-06-30T00:00:00.000ZNCT07672002: Cuidar-ME, a Web-based Psychological Intervention for (Peri)Menopausal Women: A Pilot Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07665385-trial-of-management-of-chronic-tinnitus-by-sound-therapy-and-cogniti-087a6894195182eePharma Surgeen2026-06-30T00:00:00.000ZNCT07665385: Trial of Management of Chronic Tinnitus by Sound Therapy and Cognitive Behavioral Therapyhttps://www.pharmaradar360.com/article/nct07619534-collection-of-csf-samples-from-participants-with-metastatic-triple-n-499b6b2cc3691899Pharma Surgeen2026-06-30T00:00:00.000ZNCT07619534: Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastaseshttps://www.pharmaradar360.com/article/nct07597941-lisaftoclax-for-prevention-of-differentiation-syndrom-in-acute-promy-48a333dd1d990a07Pharma Surgeen2026-06-30T00:00:00.000ZNCT07597941: Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients